SCHEMBL11928202

SCHEMBL11928202

O=C(O)N1[C@H](Cc2ccc([N+](=O)[O-])cc2)CC[C@@H]1[C@H](O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 1/20 0.47
▸ HTT P42858 2/20 0.44
▸ CCR5 P51681 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ DRD4 P21917 1/20 0.41
▸ SIGMAR1 Q99720 2/20 0.40
▸ CACNA1G O43497 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11928204 1.00 HTR2A (0.47) HTR2AHTTCCR5MAPTLMNA
SCHEMBL11928206 1.00 HTR2A (0.47) HTR2AHTTCCR5MAPTLMNA
SCHEMBL4565483 1.00 HTR2A (0.47) HTR2AHTTCCR5MAPTLMNA
SCHEMBL11928203 1.00 HTR2A (0.47) HTR2AHTTCCR5MAPTLMNA
SCHEMBL1199448 0.86 HTR2A (0.41) HTR2AHTTCCR5MAPTLMNA
SCHEMBL908450 0.86 HTR2A (0.41) HTR2AHTTCCR5MAPTLMNA
SCHEMBL3844676 0.84 SOAT1 (0.36) HTR2ASIGMAR1OPRK1MEN1KMT2A
SCHEMBL3837500 0.84 SOAT1 (0.36) HTR2ASIGMAR1OPRK1MEN1KMT2A
SCHEMBL11928187 0.84 SOAT1 (0.36) HTR2ASIGMAR1OPRK1MEN1KMT2A
SCHEMBL4539411 0.84 SOAT1 (0.36) HTR2ASIGMAR1OPRK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653260-B2 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2014-02-18 — — US disclosed
US-8399480-B2 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-03-19 — — US disclosed
US-20120258963-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. 2012-10-11 — — US disclosed
US-8247415-B2 Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2012-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258963-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 HTR2A 138/4885HTT 2948/4885CCR5 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback